PMC:7600245 / 27993-28414
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T106 | 357-365 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T262 | 78-84 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
| T263 | 88-89 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T264 | 153-158 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
| T265 | 325-331 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T389 | 4-8 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T204 | 0-308 | Sentence | denotes | The drug was developed at the Emory Institute for Drug Development and it was tested in a phase 1 randomized, double-blind, placebo-controlled, first-in-human study designed to evaluate its safety, tolerability, and pharmacokinetics following oral administration to healthy volunteers (NCT04392219; n = 130). |
| T205 | 309-421 | Sentence | denotes | It is now being tested in two phase 2 trials in COVID-19 patients (NCT04405570; n = 44 and NCT04405739; n = 60). |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 791 | 153-158 | Species | denotes | human | Tax:9606 |
| 792 | 366-374 | Species | denotes | patients | Tax:9606 |
| 793 | 357-365 | Disease | denotes | COVID-19 | MESH:C000657245 |